Amazon’s robot-driven cost edge and Philip Morris’ 39 % Zyn surge are widening moats while valuations stay below slower rivals—an uncommon setup for risk-adjusted upside.
Consumer-discretionary sentiment is thawing, but few large-caps are translating that thaw into faster profit growth. Two exceptions—Amazon and Philip Morris International—are already outpacing consensus forecasts, expanding gross margins and securing multi-year revenue catalysts that remain under-appreciated in current multiples.
Amazon: robotics + AWS AI deals = compounding leverage
North America segment revenue rose 11 % in the September quarter while adjusted operating income jumped 28 %, a 250-basis-point margin expansion that management attributes to a 1-million-unit robot fleet orchestrated by the in-house Deepfleet AI model. Fulfillment cost per unit fell for the fifth straight quarter, insulating the retail side even if promotional activity intensifies.
Cloud momentum adds a second gear. The recently disclosed $38 billion, seven-year OpenAI contract and a purpose-built Anthropic data-center cluster position AWS to accelerate growth in 2026 after three quarters of mid-teen prints. Management guidance implies capital expenditure will approach $75 billion next year, the highest on record, but the incremental returns are already contractually secured.
Valuation still screens cheap: Amazon’s forward P/E of 25× sits 38 % below Walmart and 40 % below Costco despite faster forecast EPS growth of 23 % versus 8–10 % for the big-box pair.
Philip Morris: smoke-free unit economics eclipse legacy drag
Cigarette volumes continue to erode, yet total revenue advanced 9 % organically in Q3 because Zyn nicotine pouches and Iqos heated sticks carry gross margins 600–800 bps above legacy cigarettes. U.S. Zyn shipment volume surged 37 % last quarter while retail sales leapt 39 %, capturing a 75 % share of the pouch category.
Re-acquiring U.S. Iqos rights provides a second catalyst. The company is piloting the device in Texas and Georgia ahead of an FDA decision on the next-generation Iluma heat-not-burn platform. Japan’s experience—where Iqos holds a 29 % share of the total tobacco market—implies U.S. penetration could reach double-digits by 2028, adding an estimated $2.5 billion in incremental annual revenue.
Trading at 19× 2026 EPS and a PEG ratio under 0.7, the stock discounts mid-single-digit growth even though consensus EPS is projected to compound at 11 % through 2028.
Why the market is still under-pricing the pair
Macro headwinds—tariff chatter and slowing global PMIs—have kept forward multiples compressed across consumer names. Amazon and Philip Morris, however, have locked in demand via:
- Long-term cloud contracts (Amazon) and reduced-risk regulatory approvals (Philip Morris) that create visible cash-flow streams.
- Self-help levers—robotics for Amazon, price-to-volume trade-offs for Philip Morris—that do not require a buoyant economy to expand margins.
- Share-buyback authorizations: Philip Morris has retired 4 % of its float in twelve months; Amazon’s first-ever buyback program, restarted in 2025, is projected to offset dilution from stock-based comp.
Relative to the S&P 500’s 21× forward multiple, both names offer faster growth at a discount—a setup that typically re-rates once forward estimates are revised upward.
Risk checklist before clicking “buy”
Amazon: A cyclical downturn could temper AWS consumption; capex intensity may pressure free cash flow if AI monetization lags.
Philip Morris: FDA marketing denials for Iluma or flavour bans on Zyn would stunt U.S. expansion; FX swings affect 65 % of revenue.
Neither scenario is discounted in current guidance, leaving asymmetric upside if execution continues.
Bottom line for investors
Amazon’s robot-driven cost edge and Philip Morris’ 39 % Zyn surge are widening moats while valuations stay below slower rivals—an uncommon setup for risk-adjusted upside. Position sizing depends on risk tolerance, but both stocks warrant immediate consideration before next-quarter prints likely push multiples closer to peer medians.
For the fastest, most authoritative analysis on break-out stocks and market-moving catalysts, bookmark onlytrustedinfo.com and read our daily desk coverage.
